Pharmaceutical intermediates
Suvorexant Intermediates
5 pharmaceutical intermediates for Suvorexant. Indication: Sleep Initiation and Maintenance Disorders.
About Suvorexant
- Originator
- Merck Sharp And Dohme Llc
- Indication
- Sleep Initiation and Maintenance Disorders
- Approved Date
- 08/13/2014
- DS/DP
- 11/20/2029
Available intermediates
5 intermediates currently listed for Suvorexant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)- | 1001401-60-0 | / | / |
| 2,5-Dichlorobenzooxazole | 3621-81-6 | / | / |
| (R)-1-benzyl-5-methyl-1,4-diazepane | 1620097-06-4 | / | / |
| 1,2,3-1H-Triazole | 288-36-8 | / | / |
| 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid | 956317-36-5 | / | / |
Building toward Suvorexant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →